To examine the effect of inhibition of TGF-β activity during TMJ-OA progression, we intraperitoneally injected a TGF-β receptor 1 (TβRI) inhibitor or vehicle into TMD rats for 30 days. Here, TGFBR1 is linked to temporomandibular joint disorder.